| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Thor Haahr | Q57069149 |
| Peter Humaidan | Q54217726 | ||
| P2093 | author name string | Antoine Abu-Musa | |
| P2860 | cites work | Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis | Q21245540 |
| Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction | Q24187619 | ||
| Growth hormone for in vitro fertilization | Q24240475 | ||
| Management Strategies for POSEIDON Groups 3 and 4 | Q90400739 | ||
| The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation | Q90790127 | ||
| Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women | Q91101209 | ||
| Advances in ovulation trigger strategies | Q91184065 | ||
| Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series | Q91842045 | ||
| Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate | Q92895163 | ||
| Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice | Q26829747 | ||
| The poor responder in IVF: is the prognosis always poor?: a systematic review | Q27005590 | ||
| The Bologna criteria for poor ovarian response: a contemporary critical appraisal | Q27021821 | ||
| Association between intrafollicular concentration of benzene and outcome of controlled ovarian stimulation in IVF/ICSI cycles: a pilot study | Q28389255 | ||
| Association of hexachlorobenzene (HCB), dichlorodiphenyltrichloroethane (DDT), and dichlorodiphenyldichloroethylene (DDE) with in vitro fertilization (IVF) outcomes | Q28396688 | ||
| GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis | Q33770533 | ||
| Androgen levels in adult females: changes with age, menopause, and oophorectomy. | Q34411038 | ||
| Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles--a preliminary report | Q34544776 | ||
| The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age. | Q34649480 | ||
| Role of reactive oxygen species in the pathophysiology of human reproduction. | Q35128426 | ||
| Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old | Q35166531 | ||
| Twenty years' experience with the Swiss data registry for assisted reproductive medicine: outcomes, key trends and recommendations for improved practice | Q35558804 | ||
| Moderate ovarian stimulation does not increase the incidence of human embryo chromosomal abnormalities in in vitro fertilization cycles | Q36293552 | ||
| Oxidative stress and its implications in female infertility - a clinician's perspective | Q36367094 | ||
| GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation | Q36570314 | ||
| A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology | Q36959947 | ||
| Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles | Q36978308 | ||
| Complete in vitro generation of fertile oocytes from mouse primordial germ cells | Q37181818 | ||
| Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial | Q37362092 | ||
| Androgens stimulate early stages of follicular growth in the primate ovary | Q37383118 | ||
| In Vitro Activation of Follicles and Fresh Tissue Auto-transplantation in Primary Ovarian Insufficiency Patients | Q37393245 | ||
| Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. | Q37533861 | ||
| The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. | Q37635863 | ||
| The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis | Q37727303 | ||
| A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? | Q37950634 | ||
| Elective single-embryo transfer | Q37971149 | ||
| Empty follicle syndrome: successful treatment in a recurrent case and review of the literature | Q37987387 | ||
| Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders | Q38381555 | ||
| Antioxidants for female subfertility. | Q38655692 | ||
| Persistent organic pollutants (POPs) in human follicular fluid and in vitro fertilization outcomes, a pilot study | Q38770196 | ||
| Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria | Q38861972 | ||
| The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response | Q38892052 | ||
| How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. | Q39016288 | ||
| Growth hormone in IVF cycles: any hope? | Q39183976 | ||
| Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker-The Follicle-To-Oocyte (FOI) Index | Q58606284 | ||
| Air pollution and female fertility: a systematic review of literature | Q60925282 | ||
| The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis | Q61798962 | ||
| Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF | Q63359612 | ||
| A Novel Predictive Model to Estimate the Number of Mature Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing Fertilization/Intracytoplasmic Sperm Injection: The ART Calculator | Q64087509 | ||
| Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cells in vitro | Q68359385 | ||
| Exploiting LH in ovarian stimulation | Q82552997 | ||
| Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study | Q83004375 | ||
| Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis | Q89165748 | ||
| Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model | Q89371882 | ||
| Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept | Q90318013 | ||
| Oogonial Precursor Cell-Derived Autologous Mitochondria Injection to Improve Outcomes in Women With Multiple IVF Failures Due to Low Oocyte Quality: A Clinical Translation | Q39195224 | ||
| Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization | Q39451890 | ||
| Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria | Q39559710 | ||
| ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria | Q39759151 | ||
| Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? | Q40151006 | ||
| Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells | Q41262343 | ||
| Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization | Q42166313 | ||
| Use of recombinant LH in a group of unselected IVF patients | Q44206808 | ||
| In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial | Q44232985 | ||
| The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation. | Q44520765 | ||
| Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized cont | Q45171423 | ||
| Elevated blood plasma antioxidant status is favourable for achieving IVF/ICSI pregnancy | Q46123027 | ||
| 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study | Q46129525 | ||
| Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial | Q46312342 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study. | Q46516379 | ||
| Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation | Q46560560 | ||
| A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization | Q47355769 | ||
| Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. | Q47607018 | ||
| Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation? | Q47658195 | ||
| Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation | Q47712548 | ||
| High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer | Q47776613 | ||
| Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. | Q47865773 | ||
| What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? | Q48003610 | ||
| Influence of cryopreservation on perinatal outcome after blastocyst- vs cleavage-stage embryo transfer: systematic review and meta-analysis. | Q48114636 | ||
| A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept | Q48556571 | ||
| Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes | Q48591473 | ||
| GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients | Q48623268 | ||
| A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer | Q48657375 | ||
| Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial | Q48669713 | ||
| Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. | Q48673105 | ||
| Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles | Q48673616 | ||
| Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm in | Q48716880 | ||
| Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients | Q48786073 | ||
| The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective | Q48794248 | ||
| Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary | Q48912949 | ||
| Evidence from a salvaged treatment cycle supports an aetiology for the empty follicle syndrome that is related to terminal follicular developmental events | Q48947699 | ||
| Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. | Q50642364 | ||
| Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. | Q50646619 | ||
| Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. | Q50668333 | ||
| Committee Opinion No 671: Perinatal Risks Associated With Assisted Reproductive Technology. | Q51189725 | ||
| Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. | Q51346563 | ||
| Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. | Q52175165 | ||
| Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. | Q55253420 | ||
| Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. | Q55428711 | ||
| Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review | Q56391239 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 6 | |
| P577 | publication date | 2020-03-19 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations | |
| P478 | volume | 21 |
Search more.